(Q88015493)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

cardiovascular disease

1 reference

chronic renal insufficiency

inferred from title

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Bert Bammens

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Ben Sprangers

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Maarten Naesens

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

9

Dirk Kuypers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

10

Pieter Evenepoel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

2

Ruben Poesen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

Kathleen Claes

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Ruth Dietrich

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Markus Storr

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

publication date

4 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

210-216

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

uPAR: a versatile signalling orchestrator

19 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Modification of kidney barrier function by the urokinase receptor.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

HIV-1 infected lymphoid organs upregulate expression and release of the cleaved form of uPAR that modulates chemotaxis and virus expression.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Plasma levels of soluble urokinase-type plasminogen activator receptor associate with the clinical severity of acute Puumala hantavirus infection

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Utility of the plasma level of suPAR in monitoring risk of mortality during TB treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Serum suPAR in patients with FSGS: trash or treasure?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

suPAR and FSGS: the gap between bench and bedside.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

https://api.crossref.org/works/10.1038%2FKI.2014.197

1 reference

7 January 2021

Immune mechanisms involved in cardiovascular complications of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high-sensitivity C-reactive protein and soluble urokinase plasminogen activator receptor. Inflammation markers in chronic haemodialysis patients?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

p-Cresol and cardiovascular risk in mild-to-moderate kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

A new equation to estimate glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.197

7 January 2021

Identifiers

DOI

10.1038/KI.2014.197

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897037%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference